Fungus InfectionPhase 4NCT02912156
Pharmacokinetics of Two Different Formulation of Voriconazole
A Phase 4 study testing Vaway FC Tablets 200mg (Voriconazole) and VFEND FC Tablets 200mg (Voriconazole) in people with Fungus Infection, run by Yung Shin Pharm. Ind. Co., Ltd..
Trial summary
A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200 mg Tablets in Healthy Adult Subjects. Read more about this study
- Who is it for?
- Ages 20 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Fungus Infection
- What is being tested?
- Vaway FC Tablets 200mg (Voriconazole) and VFEND FC Tablets 200mg (Voriconazole)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 29 participants
- Where
- No sites listed yet
- Study dates
- Jun 2016to Aug 2016
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy adult, aged between 20 to 45 years old.
- Physically and mentally healthy subjects as confirmed by an interview, medical history review, clinical examination, laboratory tests, chest x-ray and electrocardiogram (ECG).
- No clinically significant finding in clinical examination and laboratory tests within two months (60 days) prior to administration of study medication;
- Normal or clinically not significant at the discretion of the investigator chest X-ray and ECG results within six months (180 days) prior to administration of study medication.
- Body weight was above 50 kg for male and 45 kg for female.
- The body mass index should be between 18 and 27; body mass index equals [weight (kg)]/[height (m)]2.
Show all 15Show fewer
- Laboratory determinations results were within normal range or considered not clinically significant by the investigator, including: Serum Glutamic Oxaloacetic Transaminase (SGOT, same as AST), Serum Glutamic Pyruvic Transaminase (SGPT, same as ALT), albumin, glucose, creatinine, uric acid, cholesterol, Triglycerides (TG), Gamma-Glutamyl-Transpeptidase (γ-GT), alkaline phosphatase, total bilirubin, Blood Urea Nitrogen(BUN),Hepatitis B surface antigen (HBsAg), Anti-Hepatitis C virus (Anti-HCV) and Anti-Human Immunodeficiency Virus (Anti-HIV) test.
- Hematology test results were within normal range or considered not clinically significant by the investigator, including: hemoglobin, hematocrit, White Blood Cell (WBC) count, Red Blood Cell (RBC) count, platelet count and WBC count with differential.
- Urinalysis results were within normal range or considered not clinically significant by the investigator, including: glucose, protein, RBC, WBC, epith, casts and bacteria.
- Adequate contraceptive methods must be used during two weeks prior and two weeks after to the administration of study medication.
- Female subject who was:
- Using adequate contraception since last menstruation and no plan for conception during the study.
- Non-lactating.
- Had negative pregnancy test (urine) prior to the study.
- Informed consent form signed.
Who cannot join
- A history of drug or alcohol abuse within 24 weeks prior to the study.
- History of drug allergy, allergic constitution, asthma or retinal disease.
- Myopia worse than 6.0 diopters.
- A clinically significant illness (such as hematological malignancy) within the past 4 weeks
- Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal disease within the past 4 weeks.
- Planned vaccination during the study.
Show all 11Show fewer
- Participation of any clinical investigation during the last 60 days.
- Regular use of any medication during the last 4 weeks.
- Single use of any medication during the last 2 weeks.
- Blood donation of more than 250 mL within the past 12 weeks.
- Individuals were judged by the investigator to be undesirable as subjects.
About this study
Official title: A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200mg Tablets in Healthy Adult Subjects
A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200 mg Tablets in Healthy Adult Subjects.
- Conditions
- Fungus Infection
- Being tested
- Vaway FC Tablets 200mg (Voriconazole), VFEND FC Tablets 200mg (Voriconazole)
- Keywords
- Pharmacokinetic
- Medical subject headings
- Mycoses
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vaway FC Tablets 200mg (Voriconazole)Drug
VFEND FC Tablets 200mg (Voriconazole)Drug
| Study group | Role | What they receive |
|---|---|---|
| Vaway FC Tablets | Experimental | Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing Receives: Drug: Vaway FC Tablets 200mg (Voriconazole) |
| VFEND FC Tablets | Active comparator | VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing Receives: Drug: VFEND FC Tablets 200mg (Voriconazole) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under the plasma concentration (AUC)
Measured: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Peak Drug Concentration (Cmax)
Measured: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Time to reach Cmax (Tmax)
Measured: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Elimination half-life (T1/2)
Measured: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Area under the (first) moment plasma concentration-time curve (AUMC)
Measured: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Secondary outcomes (1)
Adverse events
Measured: Within 8 weeks prior to the study, subjects were screened for their eligibility.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2016 (estimated)
- Study startJun 2016
- Primary completionJul 2016
- Study completionAug 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fungus InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Taichung Veterans General Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02912156
- Sponsor's protocol ID
- YSP-RIH3001-01
- Status last verified
- Sep 2016
- First submitted
- 21 Sep 2016
- Last updated
- 23 Sep 2016
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200mg Tablets in Healthy Adult Subjects
- ClinicalTrials.gov ID
- NCT02912156
- Acronym / sponsor ID
- YSP-RIH3001-01
- Conditions
- Fungus Infection
- Keywords
- Pharmacokinetic
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- Yung Shin Pharm. Ind. Co., Ltd.Industry (pharma, biotech, devices)
- Collaborators
- Taichung Veterans General Hospital
- Study start
- Jun 2016
- Primary completion
- Jul 2016 (actual)
- Study completion
- Aug 2016 (actual)
- First posted
- 23 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200 mg Tablets in Healthy Adult Subjects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vaway FC Tablets | Experimental | Drug: Vaway FC Tablets 200mg (Voriconazole)Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing |
| VFEND FC Tablets | Active comparator | Drug: VFEND FC Tablets 200mg (Voriconazole)VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (15 listed)
- Healthy adult, aged between 20 to 45 years old.
- Physically and mentally healthy subjects as confirmed by an interview, medical history review, clinical examination, laboratory tests, chest x-ray and electrocardiogram (ECG).
- Body weight was above 50 kg for male and 45 kg for female.
- The body mass index should be between 18 and 27; body mass index equals [weight (kg)]/[height (m)]2.
- Laboratory determinations results were within normal range or considered not clinically significant by the investigator, including: Serum Glutamic Oxaloacetic Transaminase (SGOT, same as AST), Serum Glutamic Pyruvic Transaminase (SGPT, same as ALT), albumin, glucose, creatinine, uric acid, cholesterol, Triglycerides (TG), Gamma-Glutamyl-Transpeptidase (γ-GT), alkaline phosphatase, total bilirubin, Blood Urea Nitrogen(BUN),Hepatitis B surface antigen (HBsAg), Anti-Hepatitis C virus (Anti-HCV) and Anti-Human Immunodeficiency Virus (Anti-HIV) test.
Key exclusion criteria (11 listed)
- A history of drug or alcohol abuse within 24 weeks prior to the study.
- History of drug allergy, allergic constitution, asthma or retinal disease.
- Myopia worse than 6.0 diopters.
- A clinically significant illness (such as hematological malignancy) within the past 4 weeks
- Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic, neurological, pulmonary or gastrointestinal disease within the past 4 weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vaway FC Tablets 200mg (Voriconazole) | Drug | Vaway FC Tablets |
| VFEND FC Tablets 200mg (Voriconazole) | Drug | VFEND FC Tablets |
Primary outcome
Area under the plasma concentration (AUC)
Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Peak Drug Concentration (Cmax)
Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Time to reach Cmax (Tmax)
Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Elimination half-life (T1/2)
Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
Area under the (first) moment plasma concentration-time curve (AUMC)
Time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr
1 secondary outcome
Adverse events
Time frame: Within 8 weeks prior to the study, subjects were screened for their eligibility.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2016.
Related trials for Fungus Infection
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Active, not recruitingPhase 2
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
Pneumococcal Disease
Not yet recruiting
Early Pathophysiology of Hidradenitis Suppurativa and Prediction of the Risk of Progression: a Prospective Cohort
Hidradenitis Suppurativa (HS)
Active, not recruitingPhase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Mycosis Fungoides, Lymphomatoid Papulosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Vaway FC Tablets 200mg (Voriconazole) and VFEND FC Tablets 200mg (Voriconazole) in people with Fungus Infection, run by Yung Shin Pharm. Ind. Co., Ltd..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under the plasma concentration (AUC) (time frame: Plasma sample: 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24 and 36 hr). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2016.